Contrast media use in patients with chronic kidney disease undergoing coronary angiography: A systematic review and meta-analysis of randomized trials

Pandya, Bhavi; Chalhoub, Jean M.; Parikh, Valay; Gaddam, Sainath; Spagnola, Jonathan; El‐Sayegh, Suzanne; Bogin, Marc; Kandov, Ruben; Lafferty, James; Bangalore, Sripal

doi:10.1016/j.ijcard.2016.11.170

Cited by 34 publications

(23 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…21,22 Numerous studies of patients undergoing coronary angiography have demonstrated AKI rates of w13%, which exceeds the average AKI rates of 5% to 6% associated with intravenous CM exposure. 13,[23][24][25] One conclusion of these results, although controversial, is that intra-arterial delivery of CM is more nephrotoxic compared to intravenous administration. [26][27][28] Statements that intra-arterial CM administration presents a higher concentration of CM to the kidney are only true when intra-arterial contrast is given in the aorta above or at the level of the renal arteries and possibly with high-dose left ventriculography (first-pass renal exposure).…”

Section: Comparison Of Cin With Intra-arterial and Intravenous Contramentioning

confidence: 99%

The Controversy of Contrast-Induced Nephropathy With Intravenous Contrast: What Is the Risk?

Rudnick

Leonberg‐Yoo

Litt

et al. 2020

American Journal of Kidney Diseases

120

View full text Add to dashboard Cite

Section: Comparison Of Cin With Intra-arterial and Intravenous Contramentioning

confidence: 99%

The Controversy of Contrast-Induced Nephropathy With Intravenous Contrast: What Is the Risk?

Rudnick

Leonberg‐Yoo

Litt

et al. 2020

American Journal of Kidney Diseases

120

View full text Add to dashboard Cite

“…In literature there are various meta-analyses comparing LOCM and IOCM in terms of nephrotoxicity. Some studies conclude that there are no significant differences in the incidence of CI-AKI between LOCM and IOCM (Biondi-Zoccai et al, 2014;Eng et al, 2016;Heinrich et al, 2009;Pandya et al, 2017;Reed et al, 2009), but other studies report greater safety of the IOCM compared with LOCM (Laskey et al, 2009;Xiong et al, 2018). Most of the observational studies on "all-comers" patients did not find a higher profile of kidney safety for IOCM compared with LOCM (Azzalini et al, 2018b;Briguori et al, 2005).…”

Section: Contrast Media Osmolality To Reduce the Risk Of Contrast-indmentioning

confidence: 99%

Contrast induced acute kidney injury in interventional cardiology: an update and key guidance for clinicians

Ronco

Tarantini²,

McCullough

2020

Reviews in Cardiovascular Medicine

View full text Add to dashboard Cite

Contrast-induced acute kidney injury (CI-AKI) is a serious complication that can affect outcome and prognosis of patients undergoing percutaneous diagnostic and interventional procedures in catheterization laboratories. There have been advancements in case definition and epidemiology. Additionally strategies have emerged that are positioned to have impact in the catheterization laboratory for patients undergoing cardiovascular procedures. The aim of this review is to provide the state-of-the-art of diagnosis, prevention and management of CI-AKI in interventional cardiology.

show abstract

“…However, clinical practice and most studies on CI nephropathy prefer the first definition as a simpler one with superior correlation with clinical outcomes [1,7,[16][17][18][19][20][21].…”

Section: Introductionmentioning

confidence: 99%

Contrast-induced Acute Kidney Injury: A Contemporary Review

Khilchuk¹,

Власенко²,

Scherbak³

et al. 2018

Int J Ren Dis Ther

View full text Add to dashboard Cite

Clinically significant Contrast-Induced Acute Kidney Injury (CIAKI) is a severe complication of interventional contrast-based procedures of all kinds. It involves high morbidity, mortality, social and financial losses. Acute renal damage after coronary angiography or percutaneous coronary intervention may occur in 1-2% of cases in the general population or 50+% of cases with high CIAKI exposure. It is essential to detect high-risk patients with renal damage as a major and frequent CIAKI predisposing factor. There are novel biomarkers with rapid or nearly instant response to acute subclinical contrast-induced renal damage, which are highly valuable in CIAKI diagnosis and for this reason desire deeper clinical research. Despite a number of controversies, prophylactic and therapeutic measures are practically the same in a vast majority of guidelines. An intravenous 0.9% NaCl solution remains the only proven measure in CIAKI prophylaxis and treatment, while the use of other pharmacological approaches still needs more relevant prospective clinical research. The aim of this paper was to review contemporary evidencebased CIAKI data.

show abstract

Contrast media use in patients with chronic kidney disease undergoing coronary angiography: A systematic review and meta-analysis of randomized trials

Cited by 34 publications

References 35 publications

The Controversy of Contrast-Induced Nephropathy With Intravenous Contrast: What Is the Risk?

The Controversy of Contrast-Induced Nephropathy With Intravenous Contrast: What Is the Risk?

Contrast induced acute kidney injury in interventional cardiology: an update and key guidance for clinicians

Contrast-induced Acute Kidney Injury: A Contemporary Review

Contact Info

Product

Resources

About